Thousands of mRNA-based vaccines and therapies are in development, but progressing from discovery to clinical trials is far from simple. Developers need more than just capacity; they require a partner who can integrate complex workflows, ensure quality, and speed up timelines.
In BioCina’s latest article, Vice President of Business Development and Commercial Operations, Dr. Jan Bekker, explains how BioCina is developing an end-to-end RNA–LNP platform that combines microbial, plasmid DNA, mRNA, and lipid nanoparticle capabilities under one roof.
Inside the article:
- Why outsourcing to an integrated CDMO is critical for mRNA–LNP programs
- How BioCina’s foundation in plasmid DNA, microbial biologics, and sterile injectables enables a seamless expansion into RNA manufacturing
- What the new GMP infrastructure in Adelaide means for clients developing both pandemic-scale and personalized therapies
- How BioCina is preparing for the future of personalized cancer vaccines and next-generation nucleic acid therapies
With seamless support from plasmid creation to fill-finish, and the benefit of up to a 48.5% R&D tax rebate in Australia, BioCina helps innovators reduce risk, save time, and confidently reach clinical milestones.
See how BioCina is shaping the future of RNA-based therapeutics.